BVS Stock Overview
A medical device company, focuses on developing and commercializing treatments that engage and enhance the body’s natural healing process in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Bioventus Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.47 |
| 52 Week High | US$12.41 |
| 52 Week Low | US$2.85 |
| Beta | 0.90 |
| 11 Month Change | 9.24% |
| 3 Month Change | 74.32% |
| 1 Year Change | 257.32% |
| 33 Year Change | -17.06% |
| 5 Year Change | n/a |
| Change since IPO | -40.29% |
Recent News & Updates
Recent updates
Healing Numbers, Hurting Valuation: Bioventus' Mixed Bag In Q2 2024
Aug 12Bioventus: Bullish On Path To Profitability
Jan 24Bioventus: Reiterating Buy Thesis Following Q2 Earnings
Sep 08Bioventus Non-GAAP EPS of $0.10 misses by $0.06, revenue of $140.3M beats by $1.97M
Aug 11Bioventus stock rises as FDA clears SonaStar Elite for use in tumor removal
Aug 03Bioventus: Strong Value Gap, Insulated Via Leading Market Share
Jun 14Bioventus: Thoughts After An Active First Year
Mar 29Shareholder Returns
| BVS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -2.6% | -0.7% | 0.6% |
| 1Y | 257.3% | 19.4% | 30.3% |
Return vs Industry: BVS exceeded the US Medical Equipment industry which returned 19.4% over the past year.
Return vs Market: BVS exceeded the US Market which returned 30.3% over the past year.
Price Volatility
| BVS volatility | |
|---|---|
| BVS Average Weekly Movement | 11.9% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BVS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BVS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 1,030 | Rob Claypoole | www.bioventus.com |
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body’s natural healing process in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications.
Bioventus Inc. Fundamentals Summary
| BVS fundamental statistics | |
|---|---|
| Market cap | US$938.48m |
| Earnings (TTM) | -US$41.96m |
| Revenue (TTM) | US$536.89m |
1.4x
P/S Ratio-17.8x
P/E RatioIs BVS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BVS income statement (TTM) | |
|---|---|
| Revenue | US$536.89m |
| Cost of Revenue | US$179.72m |
| Gross Profit | US$357.17m |
| Other Expenses | US$399.13m |
| Earnings | -US$41.96m |
Last Reported Earnings
Jun 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.64 |
| Gross Margin | 66.53% |
| Net Profit Margin | -7.82% |
| Debt/Equity Ratio | 202.7% |
How did BVS perform over the long term?
See historical performance and comparison